The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

被引：17
|
作者：
Lonardi, S. [1 ]
Pietrantonio, F. [2 ]
Llavero, N. Tarazona [3 ]
Viladot, C. Montagut [4 ]
Bianchi, A. Sartore [5 ]
Zampino, M. G. [6 ]
Fernandez, M. E. Elez [7 ]
Vivas, C. Santos [8 ]
Mandala, M. [9 ]
Tamberi, S. [10 ]
Sciallero, M. S. [11 ]
Munoz, S. [12 ]
Lazzari, L. [13 ]
Luraghi, P. [13 ]
Torri, V. [14 ]
Cervantes, A.
Bardelli, A. [15 ]
Tabernero, J.
Siena, S.
Marsoni, S. [13 ]
机构：
[1] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy
[2] Fdn IRCCS, Dept Med Oncol, Ist Nazl Tumori, Milan, Italy
[3] Univ Valencia, INCLIVA Biomed Res Inst, Dept Med Oncol, Valencia, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Univ Milano La Statale, Dipartimento Oncol Emato Oncol, ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[6] IEO Ist Europeo Oncol, Dept Med Oncol, Milan, Italy
[7] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[8] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[9] Univ Perugia, Santa Maria Misericordia, Univ Hosp Perugia, Oncol, Perugia, Italy
[10] AUSL Romagna, Osped Infermi, Oncol Unit, Faenza, Ravenna, Italy
[11] IRCCS Osped Policlin San Martino, Med Oncol 1 Dept, Genoa, Italy
[12] Vall Hebron Inst Oncol VHIO, Cellex Ctr, Acad CRO, Barcelona, Spain
[13] IFOM AIRC Inst Mol Oncol, Precis Oncol Unit, Milan, Italy
[14] Ist Ric Farmacol Mario Negri IRCCS, Oncol, Milan, Italy
[15] IFOM AIRC Inst Mol Oncol, Gen Canc & Targeted Therapies, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA28
引用
收藏
页码：S1268 / S1269
页数：2
相关论文
共 50 条
  • [41] A prospective pharmacogenetic study of 5FU/LV in high-risk stage II and III colon cancer patients.
    Mulder, K
    Scarfe, AG
    Koski, S
    Au, HJ
    Butts, C
    Fields, A
    Razavy, H
    Graham, K
    Cass, CE
    Sawyer, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 143S - 143S
  • [42] Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO
    Conca, Veronica
    Vetere, Guglielmo
    Moretto, Roberto
    Lonardi, Sara
    Antoniotti, Carlotta
    Germani, Marco Maria
    Pietrantonio, Filippo
    Bittoni, Alessandro
    Carullo, Martina
    Salvatore, Lisa
    Boccaccino, Alessandra
    Ronzoni, Monica
    Ricagno, Gianmarco
    Toma, Ilaria
    Cupini, Samanta
    Latiano, Tiziana Pia
    Arcangeli, Giuseppina
    Masi, Gianluca
    Fassan, Matteo
    Cremolini, Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] The prognostic significance of apical lymph node metastasis in patients with high-risk stage III colon cancer
    Ishii, Kenichi
    Watanabe, Jun
    Goto, Kouki
    Suwa, Yusuke
    Nakagawa, Kazuya
    Suwa, Hirokazu
    Ozawa, Mayumi
    Ishibe, Atsushi
    Kunisaki, Chikara
    Endo, Itaru
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [44] The prognostic significance of apical lymph node metastasis in patients with high-risk stage III colon cancer
    Kenichi Ishii
    Jun Watanabe
    Kouki Goto
    Yusuke Suwa
    Kazuya Nakagawa
    Hirokazu Suwa
    Mayumi Ozawa
    Atsushi Ishibe
    Chikara Kunisaki
    Itaru Endo
    Scientific Reports, 12
  • [45] Clinical Impact of Elastic Laminal Invasion in Colon Cancer: Elastic Laminal Invasion-Positive Stage II Colon Cancer Is a High-Risk Equivalent to Stage III
    Yokota, Mitsuru
    Kojima, Motohiro
    Nomura, Shogo
    Nishizawa, Yusuke
    Kobayashi, Akihiro
    Ito, Masaaki
    Ochiai, Atsushi
    Saito, Norio
    DISEASES OF THE COLON & RECTUM, 2014, 57 (07) : 830 - 838
  • [46] Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer
    Liming Wang
    Yasumitsu Hirano
    Toshimasa Ishii
    Hiroka Kondo
    Kiyoka Hara
    Nao Obara
    Shigeki Yamaguchi
    World Journal of Surgical Oncology, 18
  • [47] Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer
    Wang, Liming
    Hirano, Yasumitsu
    Ishii, Toshimasa
    Kondo, Hiroka
    Hara, Kiyoka
    Obara, Nao
    Yamaguchi, Shigeki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [48] High-risk MSI-H stage II colon cancer: Treatment patterns and outcomes.
    Fleming, Patrick
    Chen, Chunxia
    Moore, Dirk F.
    Hochster, Howard S.
    Jabbour, Salma K.
    Berim, Lyudmyla Derby
    Spencer, Kristen Renee
    Gulhati, Pat
    Donohue, Kristen
    Patel, Nell Maloney
    Boland, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15587 - E15587
  • [49] How to improve outcome in high-risk stage III colon cancer with dMMR gene
    Abdelsalam, Y.
    Elbaiomy, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S28 - S28
  • [50] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Kyung-Ha Lee
    In Jun Yang
    Gi Won Ha
    Jaeim Lee
    Youn Young Park
    Suk Hwan Lee
    Jong Min Lee
    Jung Hoon Bae
    Eun Jung Park
    Hyungjin Kim
    Keun Young Kim
    Sanghyung An
    Ik Yong Kim
    Ji Yeon Kim
    BMC Cancer, 24
12345